NO20063501L - Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese - Google Patents

Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese

Info

Publication number
NO20063501L
NO20063501L NO20063501A NO20063501A NO20063501L NO 20063501 L NO20063501 L NO 20063501L NO 20063501 A NO20063501 A NO 20063501A NO 20063501 A NO20063501 A NO 20063501A NO 20063501 L NO20063501 L NO 20063501L
Authority
NO
Norway
Prior art keywords
tyrosine kinase
kinase inhibitors
receptor tyrosine
synthesis
intermediates
Prior art date
Application number
NO20063501A
Other languages
English (en)
Norwegian (no)
Inventor
Youchu Wang
Chew Warren
Maria Papamichelakis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20063501L publication Critical patent/NO20063501L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20063501A 2004-01-16 2006-08-01 Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese NO20063501L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53732904P 2004-01-16 2004-01-16
PCT/US2005/001384 WO2005070890A2 (en) 2004-01-16 2005-01-14 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof

Publications (1)

Publication Number Publication Date
NO20063501L true NO20063501L (no) 2006-09-28

Family

ID=34807094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063501A NO20063501L (no) 2004-01-16 2006-08-01 Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese

Country Status (20)

Country Link
US (2) US7432377B2 (es)
EP (1) EP1711467A2 (es)
KR (1) KR20060123545A (es)
CN (1) CN1930128A (es)
AR (1) AR047424A1 (es)
AU (1) AU2005206541A1 (es)
BR (1) BRPI0520812A2 (es)
CA (1) CA2553729A1 (es)
CR (1) CR8530A (es)
EC (1) ECSP066773A (es)
GT (1) GT200500008A (es)
MY (1) MY136959A (es)
NO (1) NO20063501L (es)
PA (1) PA8621501A1 (es)
PE (1) PE20050896A1 (es)
RU (1) RU2006127414A (es)
SG (1) SG149817A1 (es)
TW (1) TW200526219A (es)
UA (1) UA85698C2 (es)
WO (1) WO2005070890A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206541A1 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
RU2007139544A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способ получения 3-цианохинолинов и промежуточные соединения, полученные согласно данному способу
RU2007143161A (ru) * 2005-05-25 2009-07-10 Вайет (Us) Способы синтеза замещенных 3-цианохинов и их продуктов
WO2006127203A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
TW200808728A (en) * 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
JP5957460B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 複素環式化合物またはその使用
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
CN104284584B (zh) 2012-03-15 2019-06-04 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
PL3188642T3 (pl) * 2014-09-01 2018-10-31 Electrolux Appliances AB Zespół wspornikowy
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
CN105503720B (zh) * 2015-12-31 2018-07-03 重庆威鹏药业有限公司 来那替尼中间体的制备方法
CN107501175A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
CN107417612A (zh) * 2017-07-25 2017-12-01 广州大学 一种喹啉衍生物的合成方法
CN107501174A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
CA3098428A1 (en) 2018-04-18 2019-10-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CA2291750A1 (en) 1997-05-28 1998-12-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
WO2001055116A2 (en) 2000-01-28 2001-08-02 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7009053B2 (en) * 2002-04-30 2006-03-07 Yungjin Pharmaceuticals Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
AU2005206541A1 (en) * 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity

Also Published As

Publication number Publication date
ECSP066773A (es) 2006-11-16
PE20050896A1 (es) 2005-11-14
WO2005070890A3 (en) 2005-11-03
US20090030197A1 (en) 2009-01-29
RU2006127414A (ru) 2008-02-27
MY136959A (en) 2008-12-31
KR20060123545A (ko) 2006-12-01
US20050159446A1 (en) 2005-07-21
TW200526219A (en) 2005-08-16
UA85698C2 (ru) 2009-02-25
SG149817A1 (en) 2009-02-27
CN1930128A (zh) 2007-03-14
BRPI0520812A2 (pt) 2009-10-06
CA2553729A1 (en) 2005-08-04
WO2005070890A2 (en) 2005-08-04
AU2005206541A1 (en) 2005-08-04
EP1711467A2 (en) 2006-10-18
GT200500008A (es) 2005-08-16
PA8621501A1 (es) 2005-08-10
AR047424A1 (es) 2006-01-18
CR8530A (es) 2008-09-23
US7432377B2 (en) 2008-10-07

Similar Documents

Publication Publication Date Title
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
NO20063780L (no) Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
WO2007105058A8 (en) Pyrazole compounds
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
WO2006050109A3 (en) Novel kinase inhibitors
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
SE0400284D0 (sv) Novel compounds
NO20074177L (no) Substituerte triazolderivater som oksytocinantagonister
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application